Advances in graft-versus-host disease: emerging therapeutic strategies, biomarker discoveries, and innovative treatment approaches
-
By
-
Yilei Cui
-
Chun-Chun Gau
-
Chuang-Wei Wang
-
Chun-Bing Chen
-
Wen-Hung Chung
-
Gary J. Fisher
-
Sung Won Choi
-
June 9, 2026
-
Clinical Scorecard: Recent Developments in Graft-Versus-Host Disease: New Therapeutic Approaches, Biomarker Innovations, and Treatment Strategies
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | Immune-mediated complication post-allogeneic HSCT, involving donor immune cells attacking host tissues. |
| Target Population | |
| Care Setting | |
Key Highlights
- GVHD affects approximately 40%-60% of HSCT recipients.
- Acute GVHD can evolve into chronic GVHD, leading to significant long-term morbidity.
- New biomarkers like ST2/REG3α and novel B-cell subsets are advancing precision diagnostics.
- PTCy-based prophylaxis has reduced GVHD rates but it remains a significant complication.
- Steroid-refractory disease continues to pose challenges in management.
Guideline-Based Recommendations
Diagnosis
- Use NIH Consensus Criteria for distinguishing acute and chronic GVHD.
Management
- Consider contemporary prophylactic strategies and treatments for steroid-refractory disease.
Monitoring & Follow-up
- Monitor for infectious complications and organ dysfunction post-transplant.
Risks
- Higher-grade acute GVHD (grade III–IV) is associated with worse outcomes.
Patient & Prescribing Data
Adult and pediatric patients undergoing allogeneic HSCT.
Emerging therapies and biomarker-driven approaches are being explored for better management.
Clinical Best Practices
- Identify and manage GVHD early to reduce morbidity and mortality.
- Utilize multi-omic signatures and biomarkers for personalized treatment strategies.
Related Resources & Content
